VIVUS (VVUS) Qsymia Growth Seen at 55% in Q1 from Q4
Tweet
Share
E-mail
Get Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) could see some upside Monday following new Qsymia data out recently from Symphony.
Bloomberg Industries noted that prescriptions for Qsymia rose 55 percent from Q412 to Q113. A total of 16,451 new prescriptions were issued from October through December last year, rising to 25,572 new prescriptions for the period spanning January to March 2013.
Notably, December had 9,000 TRx, slipping to 7,669 TRx in January, the only month of lower growth.
BI notes that the data reflects promotional programs run by VIVUS, which allow users two free weeks of the low-dose and four-weeks of a medium dose at a 50 percent discount. Translation of new TRx to continuing revs is critical for the company.
Shares of VIVUS are flat at $11.93 early.
Bloomberg Industries noted that prescriptions for Qsymia rose 55 percent from Q412 to Q113. A total of 16,451 new prescriptions were issued from October through December last year, rising to 25,572 new prescriptions for the period spanning January to March 2013.
Notably, December had 9,000 TRx, slipping to 7,669 TRx in January, the only month of lower growth.
BI notes that the data reflects promotional programs run by VIVUS, which allow users two free weeks of the low-dose and four-weeks of a medium dose at a 50 percent discount. Translation of new TRx to continuing revs is critical for the company.
Shares of VIVUS are flat at $11.93 early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Stocks and yen struggle as tech troubles weigh
- US DoJ to Decide by as Soon as Late May Whether Boeing Violated Prosecution Deal - Reuters
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
